Skip to main content
. Author manuscript; available in PMC: 2013 Jan 22.
Published in final edited form as: Hematol Oncol Clin North Am. 2011 Dec;25(6):1281–1301. doi: 10.1016/j.hoc.2011.09.015

Table 1.

Summary of Open and Planned Clinical Trials with CD19-Targeted Chimeric T Cell

Cell Source Patient Population Trial Design Accompanying
Lymphodepleting
Cytotoxic Therapy
Trial
Status
Trial Site
Autologous
T cells
Relapsed or refractory CLL Phase I dose-escalation trial Cy Open US,
New York
Autologous
T cells
Relapsed or refractory, or
MRD+ ALL
Phase I dose-escalation trial Cy Open US,
New York
Autologous
T cells
MRD+ or residual disease
following frontline CLL
therapy
Phase I dose escalation
trial; consolidation therapy
following upfront
chemotherapy
Cy Open US,
New York
Autologous
T cells
Relapsed or refractory low-
intermediate grade NHL &
CLL
Phase I dose escalation trial None Open US,
Texas
Autologous
T cells
Relapsed or refractory B-cell
leukemia/lymphoma (ALL,
CLL, FL, MCL, DLBCL)
Phase I dose escalation trial None Open US,
Pennsylvania
Autologous
T cells
Relapsed or refractory FL Phase I Fludarabine +
rituximab
Open US,
California
Autologous
T cells
CD19-expressing B cell
malignancy of any type
Phase I Fludarabine + Cy Open US,
NIH
Autologous
T cells
Relapsed or refractory low-
intermediate grade NHL &
CLL
Phase I; modified T cell
infusion following
autologous-HSCT
Autologous HSCT
regimen (carmustine,
etoposide, cytarabine,
melphalan, rituximab)
Open US,
Texas
Donor-derived
EBV-specific
T cells
MRD+ or relapsed ALL
following allo-HSCT
Phase I dose escalation trial Cy Open US,
New York
Donor-derived
multivirus-
specific T cells
Relapsed B-ALL following
allo-HSCT
Phase I dose-escalation trial None Open US,
Texas
Donor-derived
T cells
Relapsed B-cell
leukemia/lymphoma
following allo-HSCT
Phase I dose-escalation trial N/A Open US,
NIH
UCB-derived
T cells
Relapsed or refractory ALL,
NHL, SLL, CLL
N/A N/A Pending US,
Texas
Autologous T
cells
High-risk, intermediate-
grade NHL
Phase I/II trial; modified T
cell infusion following auto-
HSCT
N/A Pending US,
California
Donor-derived
EBV-specific
T cells
High-risk or relapsed B-ALL
after allo-HSCT
Phase I N/A Pending Europe
(France,
Germany,
Italy, UK)

CLL: chronic lymphocytic leukemia; Cy: cyclophosphamide; MRD: minimal residual disease; ALL: acute lymphocytic leukemia; NHL: non-Hodgkin’s lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large B cell lymphoma; HSCT: hematopoietic stem cell transplant; SLL: small lymphocytic lymphoma